Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of LY3461767 in Healthy Participants
NCT04352114Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules, Blood Coagulation Factors
- Countries
- 2
01
Overview
Phase 1, randomised trial of LY3461767 in chronic heart failure (CHF) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) Considered Related to Study Drug. Started Jun 2020; status: completed.
02
Drugs
LY3461767
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on NCT04352114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04352114.